Results for extended release translation from English to Maltese

approval extended
approvazzjoni estiŻa

one vial containing risperdal consta extended release microspheres
kunjett wieħed li fih mikrosferi ta ’ risperdal consta li jintreħew bil- mod

additionally, there was no pharmacokinetic interaction between zaleplon and venlafaxine (extended release).
barra dan, ma hemmx interazzjoni farmakokinetika bejn iż-zaleplon u venlafaxin (mneħħi fuq tul ta’ żmien estiż).

there is no clinically relevant pharmacokinetic interaction of ketek and theophylline administered as extended release formulation.
ma kienx hemm interazzjoni famakokinetika rilevanti ta’ ketek meta ingħata ma` theophylline fil- forma li tinħall bil-mod.

the absorption properties of exenatide reflect the extended release properties of the prolonged-release exenatide formulation.
il-mod kif jiġi assorbit exenatide jirrifletti l-mod kif il-formulazzjoni ta’ exenatide li jerħi l-mediċina bil-mod terħi l-mediċina b’mod gradwali.

olanzapine 15 mg in study d1050231, quetiapine extended-release (xr) 600 mg in study d1050233.
olanzapine 15 mg fi studju d1050231, quetiapine b’rilaxx estiż (xr - extended-release) 600 mg fi studju d1050233.

co-administration of colesevelam and metformin extended-release (er) tablets increases the exposure of metformin.
it-teħid flimkien ta’ colesevelam u pilloli ta’ metformin li jerħu l-mediċina b’mod imtawwal (pilloli er-extended release) iżid l-espożizzjoni ta’ metformin.

the modified-release tablet has an outer coating layer that provides an immediate release of the drug and an extended release core.
il-pillola li terħi l-mediċina b’mod modifikat għandha kisja ta’ barra li terħi l-mediċina b’mod immedjat u parti ċentrali li terħi l-mediċina b’mod estiż.

the immediate-release part provides a rapid onset of absorption and the extended release part provides a more extended plasma profile of cortisol.
il-parti li terħi l-mediċina b’mod immedjat tipprovdi bidu malajr tal-assorbiment u l-parti li terħi l-mediċina b’mod estiż tagħti profil aktar estiż ta’ kortisol fil- plażma.

risperdal consta extended release microspheres in the vial must be reconstituted only in the solvent in the syringe supplied in the dose pack, and must be administered only with the needle-pro safety needle supplied in the dose pack.
mikrosferi risperdal consta li jintreħew bil- mod li qegħdin fil- kunjett għandhom jiġu rikostitwiti biss fis- solvent ta ’ ġos- siringa pprovduta fil- pakkett tad- doża, u għandu jingħata biss bil - labra ta ’ sigurtà needle- pro pprovduta fil- pakkett tad- doża.

for some prolonged release formulations, an increased release due to an extended gastric residence time may slightly increase drug exposure.
għal xi formulazzjonijiet li jerħu l-mediċina bil-mod, iż-żieda fir-reħi tal- mediċina minħabba ż-żmien itwal li hija ddum fl-istonku tista’ żżid kemxejn l-espożizzjoni għall- mediċina.

in a drug interaction study, neither intuniv nor osmotic release oral system (oros)- methylphenidate hcl extended-release were found to affect the pharmacokinetics of the other medicinal products when taken in combination.
fi studju dwar l-interazzjoni tal-mediċina, la intuniv u lanqas osmotic release oral system (oros)-methylphenidate hcl li jerħi l-mediċina b’mod estiż, ma nstabu li jaffettwaw il- farmakokinetika tal-prodotti mediċinali l-oħrajn meta jittieħdu flimkien.

instructions for needle-free vial access device risperdal consta extended release microspheres in the vial must be reconstituted only in the solvent in the syringesupplied in the dose pack, and must be administered only with the needle-pro safety needle supplied in the dose pack.
struzzjonijiet għall- apparat ta ’ aċċess għal- kunjett mingħajr labra mikrosferi risperdal consta li jintreħew bil- mod li qegħdin fil- kunjett għandhom jiġu rikostitwiti biss fis- solvent ta ’ ġos- siringa pprovduta fil- pakkett tad- doża, u għandu jingħata biss bil - labra ta ’ sigurtà needle- pro pprovduta fil- pakkett tad- doża.

fenofibrate, niacin and ezetimibe: when lomitapide was administered to steady state prior to micronised fenofibrate 145 mg, extended release niacin 1000 mg, or ezetimibe 10 mg, no clinically significant effects on the exposure of any of these medicinal products were observed.
fenofibrate, niacin u ezetimibe: meta lomitapide ngħata fi stat stabbli qabel fenofibrate mikronizzat 145 mg, niacin b’rilaxx estiż 1000 mg, jew ezetimibe 10 mg, ma ġie osservat l-ebda effett klinikament sinifikanti fuq l-esponiment ta’ xi wieħed minn dawn il-prodotti mediċinali.

coadministration of a single zaleplon 10 mg dose and venlafaxine (extended release) 75 mg or 150 mg daily did not produce any interaction on memory (immediate and delayed word recall) or psychomotor performance (digit symbol substitution test).
l- amministrazzjoni ta ’ doża unika ta ’ 10mg zaleplon u venlafaxin (mneħħi fuq tul ta ’ żmien estiż) 75 mg jew 150 mg kulljum ma jiproduċċux interazzjoni fuq il- memorja (immedjata jew ritardata fuq li wieħed jiftakar il- kliem) jew kif jaġixxi l- mekkaniżmu psikomatiku fl- individwu (f’ test ta ’ bdil bejn numri u simboli).

contents of the dose pack: • one vial containing risperdal consta extended release microspheres • one alaris smartsite needle-free vial access device for reconstitution • one prefilled syringe containing 2 ml solvent for risperdal consta • one needle-pro needle for intramuscular injection (safety 20g 2” tw needle-with needle protection device).
· labra needle- pro waħda għall- injezzjoni ġol- muskolu (labra ta ’ sigurtà 20g 2 "tw b’ apparat